{
    "clinical_study": {
        "@rank": "68862", 
        "arm_group": [
            {
                "arm_group_label": "Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of 40 mg simvastatin on Day 1"
            }, 
            {
                "arm_group_label": "Baricitinib + Simvastatin", 
                "arm_group_type": "Experimental", 
                "description": "Oral doses of 10 mg baricitinib once daily on Days 3 to 7, with a single oral dose of 40 mg simvastatin co-administered on Day 6."
            }
        ], 
        "brief_summary": {
            "textblock": "The purposes of this study are to determine the effects of baricitinib  on the time it takes\n      to remove simvastatin from the body and to look at how well-tolerated and safe baricitinib\n      is when given alone and in combination with simvastatin. Side effects will be documented.\n      The study will last approximately 7 days from the first dose to the end of the study (not\n      including screening or follow-up)."
        }, 
        "brief_title": "A Study of Baricitinib and Simvastatin in Healthy Participants", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male participants - Agree to use 2 reliable methods of birth control with female\n             partners of childbearing potential during the study and for at least 3 months\n             following the last dose of study drug\n\n          -  Female participants - Women not of childbearing potential due to surgical\n             sterilization confirmed by medical history, or menopause\n\n          -  Have a body mass index of 18.0 to 29.0 kilogram per meter square (kg/m^2), inclusive\n\n          -  Have clinical laboratory test results within the normal reference range\n\n          -  Have normal renal function\n\n          -  Have normal blood pressure and pulse rate\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in a clinical trial involving a study drug or off-label use of\n             a drug or device, or are concurrently enrolled in any other type of medical research\n\n          -  Have completed or discontinued within the last 90 days from a clinical trial\n             involving a study drug\n\n          -  Have previously completed or withdrawn from this study or any other study\n             investigating baricitinib, and have previously received baricitinib\n\n          -  Have known allergies to baricitinib, simvastatin, related compounds, or any\n             components of the baricitinib or simvastatin formulations, or history of significant\n             atopy\n\n          -  Have an abnormality in the 12-lead electrocardiogram (ECG)\n\n          -  Have a history of, or current cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine (including hypothyroidism), hematological, or\n             neurological disorders\n\n          -  Have current or recent history of myalgia or muscle weakness\n\n          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug\n             screening\n\n          -  Have a current or recent history of a clinically significant bacterial, fungal,\n             parasitic, viral (not including rhinopharyngitis), or mycobacterial infection\n\n          -  Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior\n             to the first dose\n\n          -  Have an absolute neutrophil count (ANC) less than 2 \u00d7 109/liter (L) (2000\n             cells/microliter [\u03bcL]) at screening or day prior to first dose of study drug. For\n             abnormal values, a single repeat will be allowed\n\n          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human\n             HIV antibodies\n\n          -  Show evidence of hepatitis C infection and/or positive hepatitis C antibody\n\n          -  Show evidence of hepatitis B infection and/or positive hepatitis B surface antigen\n\n          -  Are women who are lactating\n\n          -  Have been exposed to a live vaccine within 12 weeks prior to the first dose or\n             expected to need/receive a live vaccine (including herpes zoster vaccination) during\n             the course of the study\n\n          -  Intend to use over-the-counter or prescription medication (including salicylate\n             drugs) and/or herbal supplements within 14 days prior to dosing and during the study\n             or intended use of vitamin supplements from Day 1 until discharge from the Clinical\n             Research Unit (CRU)\n\n          -  Have consumed or intend to consume grapefruit or grapefruit-containing products\n             within 14 days prior to the first dose and throughout the study\n\n          -  Have donated or lost blood of more than 500 milliliter (mL) within the last 3 months\n\n          -  Have an average weekly alcohol intake that exceeds 28 units per week (males) and 21\n             units per week (females), or are unwilling to stop alcohol consumption from 48 hours\n             prior to the first dose until discharge from the Clinical Research Unit (CRU) at the\n             end of Period 2\n\n          -  History of, in the opinion of the investigator, excessive methylxanthine use within\n             the previous 6 months, such as greater than (>)6 cups of coffee (or equivalent) per\n             day\n\n          -  Currently smoke more than 10 cigarettes per day"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960140", 
            "org_study_id": "14606", 
            "secondary_id": "I4V-MC-JAGI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Baricitinib + Simvastatin", 
                "description": "Administered orally", 
                "intervention_name": "Baricitinib", 
                "intervention_type": "Drug", 
                "other_name": "LY3009104"
            }, 
            {
                "arm_group_label": [
                    "Simvastatin", 
                    "Baricitinib + Simvastatin"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Simvastatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Simvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "state": "West Yorkshire", 
                    "zip": "LS2 9LH"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of Simvastatin and Simvastatin Acid", 
                "safety_issue": "No", 
                "time_frame": "Predose through 48 hours postdose, Days 1 and 6"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the Concentration Curve from Zero to Infinity (AUC [0-\u221e]) of Simvastatin and Simvastatin Acid", 
                "safety_issue": "No", 
                "time_frame": "Predose through 48 hours postdose, Days 1 and 6"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}